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Summary 
Background: Despite negative association between 25-
hydroxy vitamin D and incidence of many chronic respiratory
diseases, this feature was not well studied in sarcoidosis.
Current study investigated the association between 25-
hydroxy vitamin D deficiency with sarcoidosis chronicity, dis-
ease activity, extra-pulmonary skin manifestations, urine cal-
cium level and pulmonary function status in Iranian
sarcoidosis patients. Results of this study along with future
studies, will supply more effective programs for sarcoidosis
treatment.
Methods: Eighty sarcoidosis patients in two groups of insuf-
ficient serum level and sufficient serum level of 25-hydroxy
vitamin D were studied. Course of sarcoidosis was defined as
Kratak sadr`aj
Uvod: Uprkos negativnoj povezanosti izme|u 25-hidroksi vi -
tamina D i u~estalosti brojnih hroni~nih respiratornih obo -
ljenja, ovaj uticaj jo{ uvek nije ispitivan u sarkoidozi. Ova
istra`ivanja izu~avaju vezu izme|u deficijencije 25-hidroksi
vitamina D sa stepenom hroni~nosti kod sarkoidoze,
aktivnosti oboljenja, ekstra pulmonalnih ko`nih manifestaci-
ja, nivoa kalcijuma u urinu i statusa pulmonalne funkcije kod
Iranskih pacijenata sa sarkoidozom. Rezultati ovih izu~avanja
sa budu}im istra`ivanjima mogu ukazati na mnogo bolji
uspeh u tretmanu sarkoidoze.
Metode: Prou~avano je osamdeset pacijenata sa sarkoido-
zom podeljenih u dve grupe u odnosu na insuficijentni i
zadovoljavaju}i nivo 25-hidroksi vitamina D. Stepen sarko i -
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Introduction
Sarcoidosis is a multi-organization disease char-
acterized by granuloma formation and enhanced
immune operation activities (1, 2). Several studies
have advocated that the innate immune failure in
responding to persistent antigens causes Granuloma
formation of sarcoidosis (1–3). Sarcoidosis disease
occurs in winter and in regions with increased latitude
in which lack of sun-exposure leads to vitamin D defi-
ciency (4, 5). Vitamin D pro hormone plays many
potential roles in immune regulatory structure (5, 3).
As explained in third national health and nutrition sur-
vey, vitamin D deficiency is associated with sarcoidosis
prevalence (6). Indeed, sarcoidosis treatment with
corticosteroids leads to osteoporosis, which so physi-
cians include calcium and vitamin D (CAD) supple-
ments in line with routine treatment. But, some con-
cerning issues about sarcoidosis insist. In this light,
hypercalcemia is a known feature of sarcoidosis in 5
to 11% of cases (7, 8). Activated macrophages in the
sarcoidosis granuloma are responsible for overpro-
duction of vitamin D3 active form.
Overproduction of active form of vitamin D3
(calcitriol or 1,25-dihydroxy vitamin D (1,25(OH)2D)),
provides hypercalcemia, hypercalciuria and osteoar-
ticular manifestations (9–12). In addition, hyper-
parathyroidism can cause hypercalcemia (1). In such
cases although vitamin D serum level deficiency
insists, but 1,25(OH)2D normal serum level remains
a prime obstacle in efficiency of 1,25(OH)2D evalua-
tion (10, 13, 14). Most sarcoidosis patients exhibit
normal levels of 1,25(OH)2D. But, these patients
represent low levels of 25-(OH)D (15, 16). As a
result, measuring Vitamin D-25 as the major circulat-
ing form of vitamin D is the most efficient administra-
tor to test the adequacy of vitamin D level (1, 17). 
Objectives
Negative association was reported between 25-
hydroxy vitamin D, active sarcoidosis, sarcoidosis chro -
nicity and pulmonary function status in sarcoidosis
patients, in recent studies (1, 4, 5, 18). But, correlation
of 25-(OH)D status with sarcoidosis factors has not
been yet studied in Iranian sarcoidosis population. The
purpose of this non-experimental de signed survey was
to investigate association of 25-hydroxy vitamin D defi-
ciency with sarcoidosis chronicity, active form of dis-
ease, skin extra-pulmonary manifestations, urine calci-
um and pulmonary function status in a group of Iranian
sarcoidosis patients at referral respiratory hospital of
Iran. Since this study is the first study of its kind, the
results will be more effective treatment of Iranian
patients by considering the level of 25(OH)D.
Material and Methods
Study Design
This correlational descriptive study was conduct-
ed at the sarcoidosis clinic of Masih Daneshvari
Hospital, Tehran. To figure the possible correlations
between vitamin D status and other limits in sarcoidosis
patients, this study was conducted between November
2013 and November 2016. Thereby, the study was
approved by the Ethics Committee of Shahid Beheshti
medical sciences university (SBMU 1.REC.1393.71).
An expert methodologist estimated the study popula-
tion size due to statistics guidelines (19, 20).
Inclusion and exclusion criteria
Inclusion criteria: Greater than 18 years old sar-
coidosis patients with biopsy-proven disease and no
co existing chronic respiratory disease.
acute and chronic sarcoidosis. Pulmonary function test (PFT)
was assessed by spirometry. Skin involvements were defined
as biopsy proven skin sarcoidosis. 24-hour urine calcium
level was used to specify the disease activity. Stages of lung
involvements were obtained by CT-scan and chest X-ray. The
statistical analyses were evaluated using Statistical Package
for the Social Sciences.
Results: A significant negative correlation was obtained
between vitamin D deficiency in sarcoidosis patients and dis-
ease chronic course and stages two to four of lung involve-
ments. Considering other parameters of the disease and vita-
min D deficiency, no significant correlation was detected.
Conclusions: In conclusion, results of the current study
implies in the role of vitamin 25(OH)D deficiencies in pre-
dicting the course of chronic sarcoidosis. Furthermore, it was
concluded that vitamin 25(OH)D deficiency can direct pul-
monary sarcoidosis toward stage 2–4 of lung involvements.
Keywords: vitamin D (D014807), hypercalciuria
(D053565), sarcoidosis (D012507) 
doze je definisan kao akutna i hroni~na sarkoidoza. Pulmo -
nalni fnkcionalni test (PFT) je izveden spirometrijom.
Uklju~enost ko`e je definisana biopsijom. Nivo kalcijuma u
24-urinu je kori{}en za dokazivanje stepena aktivnosti obo -
ljenja. Stepen uklju~enosti promena na plu}ima je dobijen
primenom CT-skenera i snimanjem plu}a rendgenski. Za
statisti~ku procenu rezultata kori{}en je statisti~ki program
Social Sciences (SPSS).
Rezultati: Dobijena je zna~ajno negativna korelacija izme|u
deficijencije vitamina D kod pacijenata sa sarkoidozom i
hroni~nog toka bolesti i stupnjeva u dva do ~etiri plu}na ste-
pena. Nije na|ena zna~ajna korelacija izme|u drugih para-
metara oboljenja i deficijencije vitamina D.
Zaklju~ak: Mo`e se zaklju~iti da dobijeni rezultati ukazuju na
ulogu deficijencije vitamina 25(OH)D u predvi|anju toka
hroni~ne sarkoidoze. Tako|e, mo`e se zaklju~iti da deficijen-
cija vitamina 25(OH)D mo`e ukazati na pulmonalnu sarkoi -
dozu sa uklju~enjem plu}a stepena 2–4.
Klju~ne re~i: vitamin D (D014807), hiperkalciurija
(D053565), sarkoidoza (D012507)
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Exclusion criteria: The smoker or tuberculosis
patient. Disease with vitamin D levels changing prop-
erties. 
Study subjects 
Forty sarcoidosis patients with 25(OH)D 50
nmol/L or less were selected as experimental group
which was comprised of two subgroups: deficient
group with 25(OH)D ≤ 25 nmol/L and insufficient
group with 27.5  25(OH)D 0 nmol/L (6). To cut diffi-
culties of two unequal groups’ analyses, 40 unknown
sarcoidosis patients with 25(OH)D > 50 nmol/L
defined as enough vitamin D were included in the
control group. Groups were selected without consid-
ering the exact result of vitamin D level or other
required clinical and para clinical parameters data
such as the amount of CD4/CD8 T cell ratio, Angio -
tensin-converting enzyme blood levels and the radio-
logical stage of the disease. All patients signed the
written consent forms in regard of human rights and
patient's privacy. On the same day of disease diagno-
sis, the blood samples, 24-hour urine, CT-scan and
chest X-ray (CXR) were got. The patients without
parenchymal lesions were defined as stage 0–1 of the
lung disease and the patients with parenchymal lesions
were classified in stage 2–4 of the lung disease.
Patients underwent primary tests such as parathyroid
test. Pulmonary function test (PFT) was performed by
spirometer (Spiro lab II, Italy) on the basis of the
European Respiratory Society criteria (18). Forced
expiratory volume in the 1st second (FEV1); forced
vital capacity (FVC) and the FEV1/FVC were expres -
sed as a percentage of the reference values and mil-
liliters (mm) (21). The primary demographic data,
such as age, gender, smoking status, course of dis-
ease and the time of diagnosis were also recorded in
the sarcoidosis clinic forms. Extra-pulmonary skin
involvements were characterized by dermatologist.
Sarcoidosis patients were registered in the national
sarcoidosis patient’s registry scheme (http://nritld-
rer.ir/#/Sarcoidosis/). Finally, patients received rele-
vant to the involved organ and disease severity steroid
treatment or oral non-steroidal anti-inflammatory
drugs. Vitamin D supplementations were prescribed
with vitamin D deficiency. 
Vitamin D-25(OH) serum level
Vitamin D-25(OH) serum level was assessed
using the Elecsys® Vitamin D test by electro-chemo-
luminescence method (ECLIA). In this regard, Roche
reagents (Roche Diagnostics GmH, Mannheim,
Germany) were utilized. Following values was used to
define different 25-OH-vitD serum levels: 
A) Deficiency: 25(OH)D ≤ 25 nmol/L serum
level. 
B) Insufficiency: a serum level of 27.5 nmol/L –
50 nmol/L 25(OH)D.
C) Sufficient: a serum level of >52.5 nmol/L
25(OH)D.
Course of sarcoidosis
Lofgren syndrome as the acute form of sar-
coidosis was defined as treatable disease in less than
2 years. Chronic sarcoidosis was defined as the form
of the disease in which both symptoms and signs of
disease remained stable and active for over two years
despite the therapy. Patients were followed up for
three years to pursue the disease symptom improve-
ment and managing everyday tasks without com-
plaints of disease.
Disease activity 
24-hour urine calcium level was used to specify
the active form of disease. The normal range of 24-
hour urine calcium level was considered 100 to 300
mg/24h. The amounts above the greatest level were
defined as hypercalciuria.
Statistical analysis
The statistical analyses were evaluated using
Statistical Package for the Social Sciences (SPSS) (ver.
22.0; SPSS Inc. Chicago, IL, USA) software.
Statistical analyses were conducted under internation-
al statistical reporting standards (22). So, descriptive
variables like 25-OH-vitD serum level were expressed
as mean (±standard deviation) or median (mini-
mum–maximum). Categorical shifts were expressed
as frequencies and percentages. Shapiro-Wilk
Normality test for normality of distribution showed
that 25-OH-vitD distribution was not normal. P value
of < 0.05 was significant. After classifying patients
into two groups due to vitamin D, correlation between
vitamin D deficiencies with qualitative variables were
tested using Pearson Chi-Square test and correlation
between vitamin D deficiencies with quantitative vari-
ables were tested using two independent sample
Mann-Whitney test.
Results
Normal distribution was only got in FEV1% vari-
able by Shapiro-Wilk normality test. 80 biopsy proven
sarcoidosis patients were studied during one year.
Age and sex central Indices were approximately same
in both groups. The mean age was 46.3 ± 8.1 with
the range of 19–78 yrs. Most of patients were in the
40–50-year old age group. Regarding the sex item,
female patients were predominant (n=48, 60%)
(Table I). Suggesting vitamin D level; 53% of men and
48% of women patients had vitamin 25(OH)D defi-
ciencies. Considering the sex of patients, no statistical
significance correlation was found between the vita-
min 25(OH)D serum levels of male and female
patients in Chi-Square test (p=0.812). So, no statisti-
cal significance correlation was found between the
age of patients and vitamin 25(OH)D serum levels
(p=0.328). 
On the basis of seasonal distribution, spring was
the most referred season with the frequency of
26.25%. The mean of disease treatment duration in
the patients was 1.31±1.01 years, ranging from two
months (in one patient) to two years (in 21 patients).
May was the most common month for establishing
the disease in our clinic. None of the patients showed
primary hyperparathyroidism. 37 (46.2%) patients
were overweight according to the Body Mass Index
(BMI > 25). Most of the patients showed high levels
of ACE (63.7±45). Overall, the most commonly
involved organ was the respiratory tract (51 cases;
63.75%) with wheezing and crackle as the common
pulmonary abnormalities. The prevalence of joint
manifestations in patients was 41.7% and Joint man-
ifestation was a dominant feature of the patients with
a diagnosis of Lofgren syndrome (87.2%). 
Vitamin D serum level and clinical information
The value of serum level 25(OH)D in our study
was measured at the moment of referring to the clin-
ic, thus mostly in the mid-spring. The mean value was
54.32 nmol/L, the percentiles ranging from 5 nmol/L
to 145 nmol/L. No statistical significant correlation
was detected considering the vitamin D levels and
duration of sarcoidosis treatment (p=0.061). 
Skin manifestations of disease were reported in
30 (37.5%) patients. Arthritis, arthralgia and joint
swelling were seen in 16 cases (20%). No statistical
significant correlation was obtained between vitamin
D levels and categorical variable skin manifestations
of disease (independent sample Mann-Whitney test)
(p=0.706). 
With respect to CT-scan chest X-ray (CXR)
results, patients were classified into a group with
lymph node involvement, (stage 0–1 of the lung dis-
ease) (38.7%) and a group with parenchymal lesions,
(stage 2–4 of the lung disease) (61.3%). When ana-
lyzing the lung involvements of sarcoidosis (parenchy-
mal vs. non-parenchymal) in the light of vitamin
25(OH)D deficiency, a statistically significant negative
correlation was found in patients with parenchymal
lung involvements of sarcoidosis and low levels of
serum vitamin 25(OH)D (Pearson Chi-Square=
4.266; df=1; p=0.039). 72% of sarcoidosis patients
with vitamin D deficiency showed parenchymal
involvement. This proportion was 50% in sarcoidosis
patients with enough vitamin D serum level. In con-
trast, no statistically significant correlation was
obtained between the patients’ lymph node involve-
ment and the levels of vitamin 25(OH)D (Mann-
Whitney test; p=0.243).
Studied sarcoidosis patients were contained of
47 (58.8%) acute sarcoidosis patients and 33
(41.3%) chronic sarcoidosis patients. About, 55% of
sarcoidosis patients with vitamin D deficiency showed
chronic disease. Only 28% of sarcoidosis patients with
sufficient vitamin D serum level showed chronic dis-
ease. Considering the course of sarcoidosis (acute vs.
chronic), a significant positive correlation was found
in patients with chronic disease, in the light of vitamin
25(OH)D deficiency (Pearson Chi-Square=4.142;
DF=1; p=0.012) (Table I).
The mean urinary calcium level was 189.7 ±
111.9 mg/24hr with the range of 19–789 mg/24hr.
18.9% of patients showed hypercalciuria. Absolute
vitamin 25(OH)D deficiencies were identified in
patients with high levels of calcium in the 24 hr urine
sample. No significant correlation was obtained
between the continuous variable urinary calcium level
(24 hour urine) and serum levels of vitamin D in
current study (Spearman correlation test) (p=0.053)
(Figure I).
Considering the correlation between vitamin D
serum levels and the continuous variable pulmonary
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Table I Vitamin 25(OH)D level (nmol/L) and course of sar-
coidosis.
25(OH)D
TotalCourse of 
sarcoidosis 25(OH)D>50 25(OH)D>50
47 29 (72.5%) 18 (45.0%) Acute 
33 11 (27.5%) 22 (55.0%) Chronic
80 40 40 Total
1000.00 57
26
*
800.00
600.00
400.00
V
C
a2
4H
r
Vitamin D – Sufficient Vitamin D – Deficient
vitd_cat
.00
200.00
Figure 1 24 hr. urine calcium level (mg/24hrs) box plot
based on level of vitamin D. 
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function FEV1 and FVC, no statistically significant
correlation was obtained in current study (Spearman
correlation test) (p=0.289, p=0.084). However, FVC
in patients with vitamin D levels above 50 nmol/L
included a mean of 340 mL higher than patients with
≤50 nmol/L serum vitamin 25(OH)D. In this case
FEV1was 220 mL higher. Nevertheless, no statistically
significant differences was obtained between the vol-
umes of FEV1 and FVC in patients with vitamin D lev-
els above 50 nmol/L and the patients with serum vita-
min 25(OH)D ≤50 nmol/L.
Discussion
Ever since the first study was tested on the rela-
tionship between chronic respiratory diseases and
vitamin D as a regulatory factor, many studies were
conducted worldwide on this issue (23). But, the
association of vitamin D deficiency with different fea-
tures of sarcoidosis is not still well-studied (1). The
purpose of this study was to investigate the relation
between vitamin 25(OH)D serum level with Course of
sarcoidosis, Status of Pulmonary function, Skin extra-
pulmonary involvement, Lung involvement stage and
Disease activity among sarcoidosis cases of Iran. 
The highest annual incidence of sarcoidosis is
found in northern Europe with 5–40 cases per
100,000 people (8, 22). Sarcoidosis incidence in Iran
is not obvious. Based on the registry organization of
Iranian Sarcoidosis patients in Referral Masih danesh-
vari hospital, Tehran, the incidence of sarcoidosis in
Iran is almost 1–2 cases per 100,000 people. Vitamin
D deficiency is considered playing an important role
in sarcoidosis development (23). In people living in
regions with far areas from the Equator, lack of sun-
exposure leads to vitamin D deficiency. Vitamin D
deficiency and chronic course of sarcoidosis occur
with a higher incidence in dark-pigmented individuals
and African-Americans living in the Southern United
States (2, 8). Iran is a country with low latitude (32°
00' N) and white skinned population. This confirms
higher incidence of acute course of sarcoidosis
among the studied patients. 
The diagnosis of majority of our sarcoidosis
patients was established in May, however, on average,
patients are involved for over 3 months before diag-
nosis. Due to poverty, many Iranian patients postpone
visiting health care providers. Duration of sarcoidosis
diagnosis is there for extended in Iran. Based on this,
we may conclude that sarcoidosis occurred in our
patients in January to February, when vitamin D
serum levels are insufficient.
Study of vitamin D was tested on 25(OH)D
serum level in our study. Current study design was
based on earlier studies represented that free
25(OH)D showed higher correlation with the actual
vitamin D deficient states than 25(OH)D (23). Similar
to some earlier studies, female patients were predom-
inant sex group and most of patients belonged to the
age group 40–50 (n=48, 60%) (1, 20). Joint mani-
festations proportion were higher than previous
reports (14%–36%) (24). In current study 87.2% of
patients with a diagnosis of Lofgren's syndrome
showed joint manifestations under the study by
Moore (80%) (24).
With correlation between the stage of the lung
disease and parenchymal lung involvement with the
low levels of vitamin 25(OH)D, statistical significant
associations were detected (p=0.039). This is at odd
with a former study which studied 226 sarcoidosis
patients with no correlation found between stage of the
lung disease and vitamin 25(OH)D serum levels (1).
This variation may be due to different studied popula-
tions in two studies. 226 studied patients in mentioned
study were Serbians with a high incidence of chronic
course of sarcoidosis and high prevalence of vitamin D
deficiency on the basis of long latitude of their country.
Current study showed that existence of respira-
tory involvements of stage 0–1 is not correlated with
vitamin D deficiency in sarcoidosis patients. A signifi-
cant negative correlation was detected between
stages 2–4 of lung involvements in sarcoidosis
patients with 25(OH)D deficiency. This shows that
Vitamin D deficiency has an important immune mod-
ulatory impression on lung impairments in a sar-
coidosis patient.
Current study results showed that sarcoidosis
patients with acute course of disease possessed high-
er level of vitamin D serum level comparing to the sar-
coidosis patients with chronic course of disease. So,
results of the current study implies in the role of vita-
min 25(OH)D deficiencies in leading the course of
sarcoidosis to chronicity. This confirmed an earlier
study on 25(OH)D deficiencies correlation with
course of chronic sarcoidosis and data from 86 sar-
coidosis patients with 29.5% of acute patients with
25(OH)D deficiency and 64.2% of chronic patients
with 25(OH)D deficiencies (5).
Results of current study on pulmonary function-
ing statues were following an earlier study (1, 6). This
implies in that 25(OH)D deficiencies may have rela-
tion with pulmonary function reduction (↓ FVC). Since
this issue was not showed in current study, future
studies on this field are recommended.
As showed earlier, hypercalcemia and hypercal-
ciuria occur in 10% and 30% of the sarcoidosis
patients (13, 14, 25). In current study, Absolute vita-
min 25(OH)D deficiencies were recognized in
patients with hypercalciuria. Hence, we suggest that
active sarcoidosis occurs in patients with deficient
serum level of vitamin 25(OH)D. Our study confirms
an earlier work which showed that 25(OH)D deficien-
cies was a potential risk factor in emerging active type
of sarcoidosis (1). Patients with hypercalciuria are rec-
ommended avoiding the sunlight and consuming
supplementations of vitamin D. We monitor urine cal-
cium level of sarcoidosis patients to prevent renal fail-
ure in the patients.
Current study was tested on a sample size of
patients that can affect the generalization of the
results. 
Conclusion
In conclusion, results of the current study
implies in the role of vitamin 25(OH)D deficiencies in
predicting the course of chronic sarcoidosis. Vitamin
25) OH) D deficiency can lead the stage of lung
involvement in pulmonary sarcoidosis toward stage 2-
4. But, since no correlations between vitamin
25(OH)D deficiency and calcium level in urine (dis-
ease activity) or pulmonary function status were
observed, further researches in these fields are rec-
ommended.
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